Assessing the Rapidly Evolving Migraine Treatment Landscape
Acute migraine impacts 22 million women and 6 million men in the United States, and wreaks considerable physical, emotional, and financial burden on these patients. Fortunately, the science behind migraine treatment is rapidly evolving, leading to a number of novel agents launching to assist patients with migraine.
The aim of this educational center is to update physicians treating patients with acute migraine on the new mechanisms of action for migraine therapies, changes to the standard of care, breaking research , and more.
.jpg)
FDA Approves Celecoxib Oral Solution for Acute Migraine
May 8, 2020
The FDA recently approved celecoxib oral solution 25mg/mL for adults with acute migraine with or without aura...
Migraines During Pregnancy Associated with Increased Maternal Stroke Risk
June 9, 2020Women who experience migraines during pregnancy are more likely to have a stroke during pregnancy, delivery, or the postpartum period, a new study suggests...
Meta-analysis Supports CGRP-Targeted Drugs for Episodic Migraine
June 8, 2020A recent meta-analysis looked at the new class of drugs’ efficacy and safety for episodic migraine across 11 studies and found significant benefit...
AHS Updates Imaging Recommendations for Migraine
June 1, 2020New guidelines issued by the American Headache Society aim to dramatically reduce the use of neuroimaging in migraine...
.jpg "In Familial Cluster Headache, Male-to-Female Ratio Lower than Expected")
In Familial Cluster Headache, Male-to-Female Ratio Lower than Expected
May 4, 2020About 8% of people suffering from cluster headache will have a family history of the condition, and the male-to-female ratio is lower than expected in this group of patients, according to a new systematic review...
.jpg "New Research Shows Long-Term Erenumab Efficacy for Migraine Prevention")
New Research Shows Long-Term Erenumab Efficacy for Migraine Prevention
May 1, 2020Two breaking studies published in a recent Neurology supplement issue demonstrated the long-term, real-world efficacy and safety of erenumab for prevention of chronic and episodic migraine...
